Acer Therapeutics Inc. (ACER)

$2.17

-0.11 (-4.82%)
Rating:
Recommendation:
Buy
Symbol ACER
Price $2.17
Beta 0.680
Volume Avg. 0.65M
Market Cap 42.749M
Shares () -
52 Week Range 1.11-4.56
1y Target Est -
DCF Unlevered ACER DCF ->
DCF Levered ACER LDCF ->
ROE 259.31% Strong Buy
ROA -138.82% Strong Sell
Operating Margin -
Debt / Equity -225.54% Sell
P/E -
P/B -2.86 Strong Sell
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ACER news


Mr. Christopher Schelling
Healthcare
Biotechnology
NASDAQ Capital Market

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.